Exploring alternative indicators for trachoma endpoint decision-making (Uganda)

Analyze the relationships between the prevalence of the clinical sign follicular trachoma (TF) and the prevalence of infection and antibody to determine whether it may be appropriate to consider one or more alternative indicators for deciding whether trachoma programs can stop MDA.

Sites

Implementation partner(s): Uganda MOH
WHO Region: AFRO

Publications

Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies

Stephanie J. Migchelsen et al.
2017, Issue no. 11, pages 1

Notes

Email primary contact

Please log in or register